Who is on it, and how far along Every drug ChEMBL records acting on OPRK1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule 13 Protein or peptide 1 Approved9 Buprenorphine Buprenorphine SponsorIndivior ModalitySmall molecule ActionAgonist Open trials130 Nalfurafine Nalfurafine SponsorImmunis ModalitySmall molecule ActionAgonist Open trials5 Dezocine Dezocine SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials4 Samidorphan Samidorphan SponsorAlkermes ModalitySmall molecule ActionPartial agonist Open trials4 Nalmefene Nalmefene SponsorHikma Pharmaceuticals ModalitySmall molecule ActionPartial agonist Open trials3 Difelikefalin Difelikefalin SponsorCSL ModalityProtein or peptide ActionAgonist Open trials2 Butorphanol Butorphanol SponsorBristol-Myers Squibb ModalitySmall molecule ActionPartial agonist Open trials1 Anileridine Anileridine SponsorNot known ModalitySmall molecule ActionAgonist Open trials0 Levallorphan Levallorphan SponsorRoche ModalitySmall molecule ActionPartial agonist Open trials0 Phase 33 Asimadoline Asimadoline SponsorTioga Pharmaceuticals ModalitySmall molecule ActionAgonist Open trials1 Aticaprant Aticaprant SponsorJohnson & Johnson ModalitySmall molecule ActionAntagonist Open trials1 Navacaprant Navacaprant SponsorNeumora Therapeutics, Inc. ModalitySmall molecule ActionAntagonist Open trials0 Phase 22 Axomadol Axomadol SponsorGrünenthal GmbH ModalitySmall molecule ActionAgonist Open trials0 ORP-101 ORP-101 SponsorOrphoMed ModalitySmall molecule ActionAntagonist Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 29 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study of a New Induction and Dosing Schedule for Sublocade in Opioid Use Disorder Buprenorphine Phase 2 Not yet recruiting The Smart Clinic Nov 20, 2026 Low-Dose IV Buprenorphine vs Hydromorphone for Acute Pain in the ED Buprenorphine Phase 2 Not yet recruiting Stanford University Nov 17, 2026 Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia Nalfurafine Phase 1 Not yet recruiting Immunis, Inc. Oct 30, 2026 Cannabidiol in Opioid Use Disorder and Chronic Pain With Buprenorphine Buprenorphine Early phase 1 Recruiting Yale University Oct 21, 2026 Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics Buprenorphine Not applicable Not yet recruiting Vanderbilt University Medical Center Sep 24, 2026 Buprenorphine for the Management of Pain in Children With Sickle Cell Disease Buprenorphine Phase 1 Not yet recruiting Natasha Archer Sep 2, 2026 BUprenorphine Versus Morphine for Postcesarean Analgesia (BUMP) Buprenorphine Phase 4 Recruiting Icahn School of Medicine at Mount Sinai Aug 25, 2026 TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization Buprenorphine Not applicable Enrolling by invitation T. John Winhusen, PhD Aug 21, 2026 Personalized Addiction Treatment enHancement Buprenorphine Not applicable Recruiting Rhode Island Hospital Aug 21, 2026 Perioperative Dezocine Administration and Postoperative Delirium in Elderly Cardiac Surgery Patients Dezocine Not applicable Not yet recruiting Chinese Academy of Medical Sciences, Fuwai Hospital Aug 17, 2026 Efficacy of Nalfurafine for Chronic Kidney Disease-Associated Pruritus in Twice-Weekly Hemodialysis Patients: A Randomized Controlled Trial Nalfurafine Phase 4 Not yet recruiting Universitas Indonesia Aug 17, 2026 A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic Cholecystectomy Dezocine Phase 2 Not yet recruiting Affiliated Hospital of Guangdong Medical University Aug 3, 2026 Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis Nalfurafine Not applicable Not yet recruiting Chinese PLA General Hospital Jun 16, 2026 A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Aticaprant Phase 1 Recruiting Janssen Research & Development, LLC May 29, 2026 Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP Dezocine Not applicable Recruiting Zhejiang University May 27, 2026 Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease Difelikefalin Not applicable Not yet recruiting Chittagong Medical College Apr 13, 2026 Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial. Dezocine Not applicable Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Feb 10, 2026 Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP Nalfurafine Phase 4 Recruiting Zhujiang Hospital Feb 2, 2026 Nalmefene Implant in Healthy Subjects Nalmefene Phase 1 Recruiting ReacX Pharmaceuticals, Inc. Jan 8, 2026 Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study Butorphanol — Not yet recruiting Sichuan Provincial People's Hospital Sep 16, 2025 Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis Nalfurafine Not applicable Recruiting Guangdong Provincial People's Hospital Aug 1, 2025 Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). Asimadoline Phase 2 Recruiting Tioga Pharmaceuticals Jun 29, 2025 Exercise and Olanzapine-samidorphan Samidorphan Phase 4 Recruiting New York State Psychiatric Institute Dec 18, 2024 TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis Nalmefene Phase 2 Not yet recruiting Tharimmune Inc Dec 13, 2024 Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus Difelikefalin Phase 2 Recruiting Vifor Fresenius Medical Care Renal Pharma Sep 19, 2024 NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions Nalmefene Phase 3 Recruiting Nantes University Hospital Sep 14, 2022 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Samidorphan Phase 3 Recruiting Alkermes, Inc. Mar 31, 2022 Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Samidorphan Phase 3 Enrolling by invitation Alkermes, Inc. Aug 3, 2021 National Pregnancy Registry for Psychiatric Medications Samidorphan — Recruiting Massachusetts General Hospital Nov 23, 2010
Show all 29Diseases most associated with it Open Targets association score, 0 to 1; all associations Alcohol dependence 0.62 Alcohol dependence Value0.62 Pain 0.61 Pain Value0.61 Opiate dependence 0.61 Opiate dependence Value0.61 Migraine disorder 0.60 Migraine disorder Value0.60 Open Drug dependence 0.60 Drug dependence Value0.60 Pruritus 0.59 Pruritus Value0.59 Open Obesity disorder 0.58 Obesity disorder Value0.58 Major depressive disorder 0.58 Major depressive disorder Value0.58 Open Osteoarthritis 0.58 Osteoarthritis Value0.58 Open Chronic pain 0.58 Chronic pain Value0.58 Open Overweight 0.52 Overweight Value0.52 Low back pain 0.52 Low back pain Value0.52 Open Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL237 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41145 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets